As little as half the prescription sleep aids could do the job for the roughly nine million Americans who take them for chronic insomnia, a new study reports. Not only that, but, a placebo could be effective as part of their treatment plans.
The findings, which advocate for a dosing strategy of smaller and fewer doses of sleep drugs and use of placebos, would decrease the amount of medication needed to maintain medication effects over time. This contrasts sharply with the standard prescribing practices for chronic insomnia treatment.
The new approach allows a person to maximize his or her clinical gains with respect to falling and staying asleep while reducing side effects and cutting prescription drug costs.
Chronic insomnia is characterized by difficulty falling asleep or staying asleep at least three nights a week for at least one month.
Lower Side Effects
Senior author Michael Perlis, associate professor in the University of Pennsylvania’s psychiatry department and director of the Penn Behavioral Sleep Medicine Program, says:
“The clinical effects of sleeping pills cannot be relied on to last forever, and long-term use increases risk of psychological dependence and side effects including daytime drowsiness, nausea, and muscle pain. Our research found that changing the industry standard for maintenance therapy can maintain treatment responses and lower the incidence of side effects.”
The study treated 74 adults experiencing chronic insomnia with 10 mg of the sleeping pill zolpidem (Ambien) for four weeks.
Those responding to the treatment were randomized into three dosing groups for 12 weeks.
- nightly dosing with 10 mg or 5 mg
- “intermittent dosing” of 10 mg 3 to 5 days a week
- “partial reinforcement” through nightly pills in which half were 10 mg capsules and half were placebo capsules.
Quality of Sleep
All three strategies the team tested were effective in maintaining peoples’ ability to fall and stay asleep, but those in the intermittent dosing group slept worse and reported more medical symptoms and greater symptom severity than those in the other dosing groups.
“When it comes to day-to-day quality of therapeutic outcomes, the strategy we use most frequently, the intermittent doing strategy performed worst,” Perlis says. “Our findings also go against the standard practice of ‘start low and go slow,’ in favor of a ‘start high and go low’ dosing strategy in which a patient starts with 10 mg nightly and then when the desired result is reached, switch to either a lower nightly dose or intermittent dosing with placebos on non-medication nights.”
The authors see the findings as a path diverting from the tendency to increase dose over time, thus making use of these medications potentially safer in the long run with the added benefit, in the case of nightly dosing with 5mg or 10mg doses interspersed with placebos, of being up to 50 percent less expensive.
These savings could cut costs drastically for both consumers and pharmaceutical companies, as consumers take a higher percentage of placebos, the profit margin would be higher on placebos than it is on the drug.
“The full dose may or may not be required to get the initial effect,” says Perlis, “but certainly maintaining the effect can be done with less medication.”
The study also offers the first data confirming that 5 mg can be effective as a maintenance strategy. This supports the 2013 decision of the FDA that required lowering the recommended dose of the sleep medication zolpidem in non-elderly women, citing a risk of next-morning impairment, including problems with alertness while driving.
Why Do Placebos Work?
“What is particularly novel about the present study is the use of placebos on non-medication nights and that such a practice appears to extend a level of therapeutic benefit that is not seen with intermittent dosing,” Perlis says. “This effect is thought to occur owing not only to the enhancement of patient expectancy but to the conditioning of medication effects, i.e., the medication induced effects may be elicited, with conditioning, by the medication capsule itself and that this can be sustained over time with occasional use of full dose medication (partial reinforcement).”
Perlis notes that if sufficient data can be gathered to show that such conditioning is possible, in the future, this may influence how medications are prescribed for maintenance therapy.
In other words, in the future, the prescriber may not only indicate what drug, and what dose, and/or what time of day to use the medication, but also what starting dose and what schedule of medication and placebo use is needed for maintenance therapy.
[thrive_text_block color=”light” headline=””]Michael Perlis, et al.
Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study
Sleep Medicine Volume 16, Issue 9, September 2015, Pages 1160–1168[/thrive_text_block]